abnobaVISCUM Fraxini 20 mg
abnobaVISCUM Fraxini 20 mg is a medicine authorised by Swissmedic under authorisation number 68315. The authorisation holder is Future Health Pharma GmbH. The medicinal product code is Anthroposophic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 28 October 2022 and the authorisation is limited until 27 October 2027. ATC code L01CX places the medicine in the group Antineoplastic agents.
| Authorisation number | 68315 |
|---|---|
| Name | abnobaVISCUM Fraxini 20 mg |
| Full name | abnobaVISCUM Fraxini 20 mg, anthroposophisches Arzneimittel |
| Authorisation holder | Future Health Pharma GmbH |
| Medicinal product code | Anthroposophic medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01CX |
| First authorisation | 28 October 2022 |
| Authorisation validity | 27 October 2027 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | abnobaVISCUM Fraxini 20 mg, anthroposophisches Arzneimittel | A | 28 October 2022 |
| 2 | abnobaVISCUM Fraxini 2 mg, anthroposophisches Arzneimittel | A | 28 October 2022 |
| 3 | abnobaVISCUM Fraxini 0,2 mg, anthroposophisches Arzneimittel | A | 28 October 2022 |
| 4 | abnobaVISCUM Fraxini 0,02 mg, anthroposophisches Arzneimittel | A | 28 October 2022 |
| 5 | abnobaVISCUM Fraxini D6, anthroposophisches Arzneimittel | A | 28 October 2022 |
| 6 | abnobaVISCUM Fraxini D10, anthroposophisches Arzneimittel | A | 28 October 2022 |
| 7 | abnobaVISCUM Fraxini D20, anthroposophisches Arzneimittel | A | 28 October 2022 |
| 8 | abnobaVISCUM Fraxini D30, anthroposophisches Arzneimittel | A | 28 October 2022 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 8 à 1ml | Ampulle(n) | L01CX | 20.02. | A |
| 11 | 8 à 1ml | Ampulle(n) | L01CX | 20.02. | A |
| 8 | 8 à 1ml | Ampulle(n) | L01CX | 20.02. | A |
| 4 | 8 à 1ml | Ampulle(n) | L01CX | 20.02. | A |
| 14 | 8 à 1ml | Ampulle(n) | L01CX | 20.02. | A |
| 15 | 8 à 1ml | Ampulle(n) | L01CX | 20.02. | A |
| 7 | 8 à 1ml | Ampulle(n) | L01CX | 20.02. | A |
| 16 | 8 à 1ml | Ampulle(n) | L01CX | 20.02. | A |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is abnobaVISCUM Fraxini 20 mg authorised in Switzerland?
Yes. abnobaVISCUM Fraxini 20 mg is authorised by Swissmedic under authorisation number 68315, data as of 01 September 2026. The authorisation is limited until 27 October 2027.
Which dispensing category does abnobaVISCUM Fraxini 20 mg have?
abnobaVISCUM Fraxini 20 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of abnobaVISCUM Fraxini 20 mg?
The authorisation holder is Future Health Pharma GmbH. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.